ATE491448T1 - Verfahren zur herstellung eines krebsimpfstoffs - Google Patents

Verfahren zur herstellung eines krebsimpfstoffs

Info

Publication number
ATE491448T1
ATE491448T1 AT07250445T AT07250445T ATE491448T1 AT E491448 T1 ATE491448 T1 AT E491448T1 AT 07250445 T AT07250445 T AT 07250445T AT 07250445 T AT07250445 T AT 07250445T AT E491448 T1 ATE491448 T1 AT E491448T1
Authority
AT
Austria
Prior art keywords
dendritic cells
producing
cancer
tumour cell
cancer vaccine
Prior art date
Application number
AT07250445T
Other languages
English (en)
Inventor
Tan Sri Datuk Yusof Basiron
Hafid Sitti Rahma Abdul
Kanga Rani Selvaduray
Kalanithi Nesaretnam
Original Assignee
Malaysian Palm Oil Board
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Malaysian Palm Oil Board filed Critical Malaysian Palm Oil Board
Application granted granted Critical
Publication of ATE491448T1 publication Critical patent/ATE491448T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/19Dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/20Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24Antigen-presenting cells [APC]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/428Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0639Dendritic cells, e.g. Langherhans cells in the epidermis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/22Colony stimulating factors (G-CSF, GM-CSF)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT07250445T 2006-02-03 2007-02-02 Verfahren zur herstellung eines krebsimpfstoffs ATE491448T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI20060439A MY160857A (en) 2006-02-03 2006-02-03 A cancer vaccine

Publications (1)

Publication Number Publication Date
ATE491448T1 true ATE491448T1 (de) 2011-01-15

Family

ID=38057880

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07250445T ATE491448T1 (de) 2006-02-03 2007-02-02 Verfahren zur herstellung eines krebsimpfstoffs

Country Status (6)

Country Link
US (1) US7776324B2 (de)
EP (1) EP1815856B1 (de)
JP (1) JP5303113B2 (de)
AT (1) ATE491448T1 (de)
DE (1) DE602007011123D1 (de)
MY (1) MY160857A (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148321A (en) * 2007-10-02 2013-03-29 Malaysian Palm Oil Board Mpob Vitamin e supplementation to tetanus toxoid
SG11201401632WA (en) * 2011-10-20 2014-05-29 California Stem Cell Inc Antigen presenting cancer vaccine
CN110885788B (zh) * 2019-12-13 2021-08-17 北京和合医学诊断技术股份有限公司 人肠癌原代细胞、应用和培养方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458585B1 (en) * 1996-08-14 2002-10-01 Nexell Therapeutics Inc. Cytokine-free culture of dendritic cells
SK822003A3 (en) * 2000-07-28 2004-05-04 Liponova Gmbh Medicament for the immunotherapy of malignant tumours
US7651686B2 (en) * 2001-10-09 2010-01-26 Mayo Foundation For Medical Education And Research Enhancement of immune responses by 4-1bb-binding agents
EP1567014B1 (de) * 2002-12-04 2011-09-28 Baylor Research Institute Einstufiges schnellverfahren zurherstellung eines antigenbeladenen dendritenzellimpfstoffs aus vorstufen
ES2532997T3 (es) * 2005-04-22 2015-04-06 Elizabeth Stuart Uso de tocotrienoles de vitamina E para la inhibición del patógeno intracelular obligado Chlamydia

Also Published As

Publication number Publication date
JP5303113B2 (ja) 2013-10-02
DE602007011123D1 (de) 2011-01-27
US20070231351A1 (en) 2007-10-04
JP2007254458A (ja) 2007-10-04
MY160857A (en) 2017-03-31
EP1815856B1 (de) 2010-12-15
EP1815856A2 (de) 2007-08-08
US7776324B2 (en) 2010-08-17
EP1815856A3 (de) 2008-05-07

Similar Documents

Publication Publication Date Title
DE602005019064D1 (de) Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren
NO20092522L (no) Sammensetninger og fremgangsmater for a behandle kreft med cupredoxiner og CPG rikt DNA
BR112012031727A2 (pt) conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença.
BRPI0814330B8 (pt) métodos e kits cirúrgicos
BRPI0921726B8 (pt) método para preparar uma composição de implante para promover o crescimento ósseo em um mamífero
EA200801074A1 (ru) Способы получения искусственных гибридных семян
WO2008039874A3 (en) Cancer stem cell antigen vaccines and methods
GB2441939A (en) Surgical membrane
EA200802213A1 (ru) Способы лечения заболеваний крови
WO2010091049A3 (en) Diagnosis and treatment of cancer
IN2014MN01981A (de)
CL2008002089A1 (es) Compuesto para la regeneracion de tejidos que comprende al menos una sustancia derivada de sangre y acido hialuronico y/o al menos un compuesto derivado de acido hialuronico; metodo para la prepararcion de dicho compuesto.
NO20090598L (no) 6,9-disubstituerte purinderivater og deres anvendelse for behandling av hud
MX351889B (es) Composiciones y métodos anti-cxcr1.
GB2497475A (en) Kits, components and methods for tissue reconstruction
EA201001749A1 (ru) Способ лечения недифференцированного артрита
EP2560002A3 (de) Verfahren zum Isolieren und/oder Identifizieren mesenchymaler Stammzellen
FR2975890B1 (fr) Systeme et procede de tracabilite d'un systeme d'instrumentation chirurgicale
WO2007137827A8 (de) Isoliertes naturidentisches kollagen
EA201290107A1 (ru) Способ определения пациента как восприимчивого или не восприимчивого к иммунотерапии
WO2009147658A3 (en) Compositions and methods for diagnosis, prognosis and treatment of mesothelioma
ATE552866T1 (de) Verfahren zur herstellung eines azellulären organischen gewebes
ATE491448T1 (de) Verfahren zur herstellung eines krebsimpfstoffs
WO2010101358A3 (ko) 세포 또는 조직 배양용 기구
AR074406A1 (es) Celulas madre terapeuticas derivadas de monocitos humanos y un metodo para inducir celulas madre terapeuticas derivadas de monocitos humanos

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties